CAP Revises Breast and GI Reporting - Takeaways - MDSpire

CAP Revises Breast and GI Reporting

Updated protocols reflect changes in biomarker testing, staging, and accreditation

Share

1

CAP updated 14 Cancer Protocols, including breast cancer biomarker reporting and gastrointestinal stromal tumor molecular testing.
2

The revisions align pathology reporting with WHO classifications, AJCC guidance, and advancements in precision oncology.
3

The Breast Biomarker Protocol now includes updated scoring criteria for estrogen receptor, progesterone receptor, and HER2.
4

New accreditation requirements for malignant phyllodes tumors mandate the use of the CAP Breast Phyllodes Tumor protocol.
5

GIST protocols expanded to include NTRK fusion gene analysis and enhanced documentation for KIT and PDGFRA testing.